Video

Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma (mRCC).

For the phase III study presented at the 2019 Genitourinary Cancers Symposium, investigators randomized patients to receive either pembrolizumab (Keytruda) plus axitinib (Inlyta) or sunitinib (Sutent). Progression-free survival was clearly superior with the immunotherapy/TKI combination compared with the standard TKI alone, Agarwal says. Objective response rates were 59% with the combination versus 36% with sunitinib. Further, the checkpoint inhibitor and TKI combination significantly increased overall survival in these patients.

Based on this data, pembrolizumab plus axitinib seems to be a promising new option for patients with mRCC, Agarwal notes, although the complete response rates with the combination were lower than those seen the FDA-approved combination of nivolumab (Opdivo) and ipilimumab (Yervoy)—5% versus 11% in favor of the PD-1/CTLA-4 inhibitor combination. Agarwal says this is the only qualm he has with pembrolizumab plus axitinib.

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS